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Abstract 
Background: The Angolan government recommends three artemisinin-based combinations for the treatment of 
uncomplicated Plasmodium falciparum malaria: artemether–lumefantrine (AL), artesunate–amodiaquine (ASAQ), and 
dihydroartemisinin–piperaquine (DP). Due to the threat of emerging anti-malarial drug resistance, it is important to 
periodically monitor the efficacy of artemisinin-based combination therapy (ACT). This study evaluated these medica-
tions’ therapeutic efficacy in Benguela, Lunda Sul, and Zaire Provinces.
Methods: Enrollment occurred between March and July 2017. Study participants were children with P. falciparum 
monoinfection from each provincial capital. Participants received a 3-day course of a quality-assured artemisinin-
based combination and were monitored for 28 (AL and ASAQ arms) or 42 days (DP arm). Each ACT was assessed in 
two provinces. The primary study endpoints were: (1) follow-up without complications and (2) failure to respond to 
treatment or development of recurrent P. falciparum infection. Parasites from each patient experiencing recurrent 
infection were genotyped to differentiate new infection from recrudescence of persistent parasitaemia. These para-
sites were also analysed for molecular markers associated with ACT resistance.
Results: Of 608 children enrolled in the study, 540 (89%) reached a primary study endpoint. Parasitaemia was cleared 
within 3 days of medication administration in all participants, and no early treatment failures were observed. After 
exclusion of reinfections, the corrected efficacy of AL was 96% (91–100%, 95% confidence interval) in Zaire and 97% 
(93–100%) in Lunda Sul. The corrected efficacy of ASAQ was 100% (97–100%) in Benguela and 93% (88–99%) in Zaire. 
The corrected efficacy of DP was 100% (96–100%) in Benguela and 100% in Lunda Sul. No mutations associated with 
artemisinin resistance were identified in the pfk13 gene in the 38 cases of recurrent P. falciparum infection. All 33 
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Background
Malaria is the principal cause of morbidity and mortal-
ity in Angola and is endemic throughout the country. The 
disease led to more than three million cases and 7999 
deaths nationwide in 2015. In recent years, the country 
has made significant gains in reducing malaria burden 
with aggressive preventive measures, case management, 
and surveillance [1].
There are currently three medications equally recom-
mended by the Angolan Ministry of Health for treatment 
of uncomplicated malaria: artemether–lumefantrine 
(AL), artesunate–amodiaquine (ASAQ), and dihydroar-
temisinin–piperaquine (DP). These are all artemisinin-
based combinations, the drug class recommended as 
first-line malaria treatment by the World Health Organ-
ization (WHO) [2]. Artemisinin-based combination 
therapy (ACT) comprises an artemisinin derivative plus 
a partner drug; the artemisinin component has a rela-
tively short half-life and acts quickly to reduce parasite 
burden, while the partner drugs have longer half-lives 
and suppress parasitaemia for weeks post-treatment. 
These pharmacological differences are important when 
monitoring for drug resistance—inadequate clearance of 
parasitaemia in the first few days after treatment signals 
a possible problem with the artemisinin component of an 
ACT, while recurrent parasitaemia later on points more 
towards an issue with the partner drug.
WHO recommends biennial surveillance of ACT effi-
cacy to provide an early warning against the emergence 
and spread of resistance [3]. In Angola, the findings of 
such surveillance have generated international interest 
and demonstrate the need for continued monitoring [4]. 
A study of anti-malarial therapeutic efficacy in Angola 
in 2002–2003 revealed an efficacy of less than 20% for 
chloroquine [5] and encouraged the Ministry of Health 
to transition to ACT for first-line treatment of uncom-
plicated malaria [1]. Efficacy studies in 2013 and 2015 
raised concerns about possible lumefantrine resistance, 
particularly in Zaire Province where corrected efficacy 
was below the 90% WHO threshold for changing treat-
ment policy [6, 7]. Another therapeutic efficacy study 
using data from 2011 to 2013 prompted similar concern 
in Luanda [8].
Although artemisinin resistance has not yet been docu-
mented in Africa, it is widespread in Southeast Asia [9, 
10]. In 2013, a Vietnamese man with recent travel to 
Angola’s Lunda Sul Province was diagnosed with malaria 
which failed to respond to repeated dosing of artemisinin 
derivatives [11]. Ultimately, this case was inconclusive 
for artemisinin failure, largely because of uncertainty 
around the quality of medications administered and the 
role of the patient’s functional asplenia in delayed para-
site clearance [12, 13]. However, the case does emphasize 
the importance of continued surveillance, particularly as 
Africa and Asia forge closer economic links. The exten-
sive use of ACT worldwide also provides a strong selec-
tive pressure for artemisinin resistance.
Another important component of anti-malarial resist-
ance monitoring is surveillance for molecular markers 
of resistance among Plasmodium falciparum parasites. 
Numerous polymorphisms in the P. falciparum genome 
have been suggested to provide resistance to ACT, both 
to the artemisinin component and to various partner 
drugs. Certain mutations in the propeller domain of 
pfk13, for instance, have been shown to confer arte-
misinin resistance [14]. Polymorphisms in the chloro-
quine resistance transporter gene pfcrt [15], originally 
identified as a marker of chloroquine resistance, have 
also been associated with resistance to multiple drugs, 
including amodiaquine and lumefantrine. Polymor-
phisms in the gene encoding the multidrug resistance 1 
transporter (pfmdr1) have been preliminarily associated 
with both lumefantrine and amodiaquine resistance, 
with certain mutations such as N86Y having an opposite 
effect on lumefantrine and amodiaquine susceptibility 
[16, 17]. Elevated pfmdr1 copy number has been postu-
lated to confer resistance to lumefantrine [18], and, most 
recently, elevated copy number of the plasmepsin 2 gene 
(pfpm2) has been proposed as a marker for piperaquine 
resistance [19, 20].
This report presents the results of the latest round 
of therapeutic efficacy monitoring of anti-malarials in 
treatment failures in the AL and ASAQ arms carried pfmdr1 or pfcrt mutations associated with lumefantrine and amo-
diaquine resistance, respectively, on day of failure.
Conclusions: AL, ASAQ, and DP continue to be efficacious against P. falciparum malaria in these provinces of Angola. 
Rapid parasite clearance and the absence of genetic evidence of artemisinin resistance are consistent with full sus-
ceptibility to artemisinin derivatives. Periodic monitoring of in vivo drug efficacy remains a priority routine activity for 
Angola.
Keywords: Antimalarial resistance, Artemether–lumefantrine, Artesunate–amodiaquine, Dihydroartemisinin–
piperaquine, pfK13, pfmdr1, pfcrt, pfpm2
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Angola’s three fixed anti-malarial surveillance sentinel 
sites.
Methods
Study design
An in vivo assessment of the therapeutic efficacy of AL, 
ASAQ, and DP was conducted according to the stand-
ard WHO protocol [3]. Study participants were recently 
febrile children with P. falciparum monoinfection. Par-
ticipants were followed with physical exams and blood 
samples for 28–42 days after anti-malarial administration 
for development of adverse medication effects or recur-
rent parasitaemia. Molecular analyses were performed 
on samples from those experiencing treatment failure.
Study population
The study took place at anti-malarial resistance sentinel 
sites in Benguela, Lunda Sul, and Zaire that were retained 
from previous therapeutic efficacy studies [6, 7]. Ben-
guela is a southern coastal province with stable mesoen-
demic malaria transmission. Zaire is a forested province 
on the northern coast that also has stable mesoendemic 
transmission. Lunda Sul province, part of Angola’s east-
ern savannah, features hyperendemic transmission 
(Fig. 1) [1].
Enrollment was divided into six arms, and efficacy of 
each medication was assessed in two provinces. Target 
enrollment of one hundred participants per arm provided 
enough power to estimate efficacy with 95% confidence 
Zaire
AL, ASAQ
Benguela
DP, ASAQ
Lunda Sul
AL, DP
Naonal capital
Provincial capital
Fig. 1 Location of sentinel sites for therapeutic efficacy monitoring in Angola, 2017
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limits of ± 5%, assuming an expected efficacy of 95% and 
a maximum loss to follow-up and exclusion rate of 27%. 
AL and DP were evaluated in Lunda Sul, AL and ASAQ 
in Zaire, and DP and ASAQ in Benguela (Fig.  1). Two 
drugs were assessed sequentially in each site. Medication 
administration was not randomized or blinded; the first 
hundred participants enrolled at each site received the 
first ACT to be evaluated there (AL in Zaire and Lunda 
Sul or DP in Benguela), and the second hundred enroll-
ees received the second drug under evaluation (ASAQ in 
Benguela and Zaire or DP in Lunda Sul).
Screening for participants took place at two health 
facilities in each province’s capital from March to July 
2017. Study entrants were children with fever (≥ 37.5 °C) 
or a history of fever in the past 24 h, P. falciparum mono-
infection on blood smear, no signs of severe malaria on 
physical exam, no concomitant illness or severe mal-
nutrition, a haemoglobin greater than 8  g/dL, no anti-
malarials within the last 14 days, and caregivers willing to 
attend all follow-up visits with study staff. Inclusion crite-
ria were broader in Benguela compared to Lunda Sul and 
Zaire, allowing for older children (< 12 years vs. < 5 years) 
and lower parasitaemias (between 1000 and 100,000 
asexual parasites/μL vs. between 2000 and 200,000 para-
sites/μL), due to the lower level of malaria transmission 
in Benguela.
Clinical monitoring
Enrolled children received a 3-day course of one of 
the anti-malarials under evaluation, dosed accord-
ing to guidelines from the drug manufacturers. Qual-
ity-controlled AL (Ipca Laboratories, Maharashtra, 
India), ASAQ (Sanofi Aventis, Paris, France), and DP 
 (Eurartesim®; Leadiant Biosciences, Rome, Italy) were 
provided by WHO. For ASAQ and DP, which have once-
daily dosing, all three doses were given under direct 
observation of study staff. For AL, which requires twice-
daily dosing, each morning dose was directly observed. 
Evening doses were given at home, and as in previous 
studies, efforts were made to ensure correct administra-
tion of each dose. Parents or guardians were given the 
appropriate weight-based dose, called at home to confirm 
delivery of the dose, and instructed to bring the empty 
pill packages back to study staff the following morning. 
All AL doses were administered with a snack, containing 
at least 3 g of fat, to facilitate drug absorption. Parents or 
guardians were given individual packages of yogurt or 
chocolate milk to take home and were asked to bring the 
empty package back to study staff the following morning.
After each medication administration, children were 
observed for 1  h to monitor for vomiting or other side 
effects, including diarrhea, nausea, or excessive sweat-
ing. Children who vomited within half an hour after 
medication administration were given a repeat dose. 
Children who vomited between half an hour and 1 h after 
medication administration were given a repeat dose that 
was half of the original dose. Those with persistent vom-
iting were excluded from the study.
Participants made eight or ten visits to study staff over 
the course of 28 or 42  days. Participants in the AL and 
ASAQ arms were followed for 28  days, while those in 
the DP arms required 42-day follow-up due to the longer 
half-life of piperaquine [3]. All children were monitored 
daily during the 3 days of drug administration and 1 day 
following; afterwards, follow-up visits occurred weekly. 
An interval history, physical exam, thick and thin blood 
smear, and dried blood spot collection were performed at 
each visit, except for day 1 of follow-up, in which blood 
samples were only collected if a child exhibited signs of 
severe malaria. Participants’ haemoglobin was also meas-
ured every 2  weeks. Finally, participants in the AL arm 
in Zaire underwent an additional dried blood spot collec-
tion on day 7 of follow-up to measure blood lumefantrine 
levels, to provide further insight into the large number 
of late treatment failures previously observed with AL in 
this province [6, 7].
Children were excluded from follow-up if they devel-
oped a non-falciparum malaria infection, showed signs of 
severe illness, missed a follow-up visit, or took another 
anti-malarial. For the preliminary analysis, the primary 
outcomes were adequate clinical and parasitological 
response, failure to adequately clear parasitaemia, or 
recurrent P. falciparum parasitaemia. Participants were 
categorized as early treatment failures if their parasitae-
mia increased from day 0 to day 2 of follow-up, failed to 
decrease by at least 75% by day 3, was associated with 
fever on day 3, or was associated with signs of severe 
malaria on days 1–3. Participants who developed any 
parasitaemia after day 3 were classified as late treatment 
failures.
Molecular analysis
Microsatellite analysis and Sanger sequencing of P. fal-
ciparum parasites were performed on selected blood 
samples from study participants. Day 0 and day of fail-
ure samples from all cases of late treatment failure were 
genotyped by microsatellite analysis for reclassification 
as reinfection or recrudescence. Additional day 0 sam-
ples from participants not experiencing treatment failure 
were randomly selected for neutral microsatellite analy-
sis to augment the number of samples for determination 
of allele frequencies. day 0 and day of failure samples 
from all cases of late treatment failure were also assessed 
for pfK13, pfcrt, and pfmdr1 sequence and pfmdr1 and 
pfpm2 copy number.
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Genomic DNA was extracted using the QIAamp blood 
minikit (Qiagen Inc., California, USA). Seven neutral 
microsatellite loci spanning six chromosomes (TA1, 
chromosome 6; poly α, chromosome 4; PfPK2, chromo-
some 12; TA109, chromosome 6; and 2490, chromosome 
10; C2M24, chromosome 2; and C3M69, chromosome 
3) were amplified by non-nested or semi-nested PCR 
and their fragment lengths were measured [21–24]. 
Fragments of the pfcrt [25], pfmdr1 [25], and pfK13 [26] 
genes were amplified using previously published prim-
ers. Direct Sanger sequencing of the nested purified PCR 
products was performed by using a BigDye Terminator 
v3.1 cycle sequencing kit on an iCycler thermal cycler 
(Bio-Rad, California, USA). Sequence analysis was per-
formed by using Geneious R7 (Biomatters, Auckland, 
New Zealand).
Pfmdr1 copy number was assessed using a previously 
described protocol [27]. The P. falciparum β-tubulin gene 
was used as the reference gene for relative quantifica-
tion of pfmdr1 gene copy number. Each run included the 
3D7 parasite strain as a single-copy control, the W2Mef 
strain (two copies), and the Dd2 strain (three to four cop-
ies). The assay was performed using the Agilent Mx3005 
real-time PCR instrument (Agilent Technologies, Cali-
fornia, USA). The copy number was determined by using 
the relative quantification module in MxPro3005 soft-
ware (Agilent Technologies, California, USA), using the 
comparative ΔΔCT method, and rounded to the nearest 
integer.
For pfpm2 copy number analysis, the P. falciparum 
β-tubulin gene was again used for reference. The reverse 
primers of both the pfpm2 and β-tubulin genes were 
modified with the PET tag and labeled with FAM (pfpm2) 
and HEX (β-tubulin) fluorophores. The PET-PCR assays 
were performed using Agilent Mx3005pro thermocyclers 
(Agilent Technologies, California, USA).
Lumefantrine level measurement
Additional dried blood spots were collected on day 7 of 
follow-up from participants in the AL arm in Zaire. A 
volume of 50  μL of whole blood was collected on filter 
paper pre-treated with 0.75 M tartaric acid and stored at 
room temperature. Dried blood spots were eluted with 
an acidified acetonitrile solution followed by solid phase 
extraction. The extraction procedure was followed by liq-
uid chromatographic separation using a Synergi Hydro-
RP, 4 µm, 150 × 2.0 mm analytical column (Phenomenex, 
California, USA) with an isocratic mobile phase con-
taining a mixture of acetonitrile, water, and formic acid 
(70:29.8:0.2) at a flow-rate of 300  µL/min. An AB Sciex 
API 3000 mass spectrometer at unit resolution in the 
multiple reaction monitoring mode was used to monitor 
the transition of the protonated precursor ions m/z 530.0 
and m/z 539.1 to the product ions m/z 512.1 and m/z 
521.3 for lumefantrine and the internal standard, respec-
tively. Electrospray ionization was used for ion produc-
tion [28, 29].
Day 7 lumefantrine concentrations greater than or 
equal to 0.2 μg/mL were considered therapeutic [30].
Statistical analysis
Uncorrected efficacy was determined by dividing the 
number of treatment failures in each study arm by the 
total number of participants classified as either adequate 
clinical and parasitological response or treatment failure 
in that arm. Parasite clearance rates on day 2 and day 3 
of follow-up were also examined to evaluate artemisinin 
delayed response.
Kaplan–Meier estimates of survival curves were cal-
culated using the survival package in R version 3.3.2 (R 
Foundation for Statistical Computing, Vienna, Austria). 
Data from participants excluded for reasons other than 
treatment failure or incorrect enrollment were included 
in the analysis until the day of study departure.
To determine corrected therapeutic efficacy, micros-
atellite data were analysed using a previously published 
algorithm [31] that assigns each late treatment failure a 
posterior probability of recrudescence. A probability of 
more than 0.5 was considered a recrudescence, and less 
than or equal to 0.5 was designated as a reinfection.
The distribution of day 7 lumefantrine drug levels 
was compared between cases of adequate clinical and 
parasitological response and cases of recrudescence and 
reinfection using the Kolmogorov–Smirnov test. The 
proportion of participants with sub-therapeutic day 7 
lumefantrine levels was compared between cases of ade-
quate clinical and parasitological response and cases of 
recrudescence and reinfection using Fisher’s exact test.
Results
Triage and enrollment
Of 608 children enrolled in the study, 27 (4%) were lost 
to follow-up (loss to follow-up rates were 7% or less in 
all study arms), and 41 participants (7%) were excluded 
(Additional file  1). Participant characteristics at base-
line reflected the different inclusion criteria in each site 
(Table 1). Median age ranged from 2.7 years in the Lunda 
Sul DP arm to 7.1  years in the Benguela DP arm. Suffi-
cient participants completed follow-up to provide statis-
tical power in all treatment arms, with between 85 and 
94 participants reaching a primary study outcome in each 
arm.
Efficacy
Of 540 children completing follow up, 502 achieved 
adequate clinical and parasitological response, and 38 
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were classified as treatment failures (Table 2). Rates of 
parasite clearance were at least 97% on day 2 in all arms 
and 100% by day 3 in all arms (Table  3). No children 
experienced early treatment failure; all 38 treatment 
failures were late treatment failures.
The uncorrected 28-day efficacy using the Kaplan–
Meier estimate of the survival curve was 93% (88–98%) 
for AL in Zaire, 90% (84–96%) for AL in Lunda Sul, 99% 
(94–100%, 95% confidence interval) for ASAQ in Ben-
guela, and 82% (75–90%) for ASAQ in Zaire (Table 4). 
The uncorrected 42-day efficacy was 95% (90–99%) for 
DP in Benguela and 100% (100–100%) for DP in Lunda 
Sul.
The majority of the 38 late treatment failures were 
reinfections (26, 68%) rather than recrudescences (12, 
32%) by microsatellite analysis (Table  2). Late treat-
ment failures were categorized with a high degree of 
confidence, with the posterior probability of recrudes-
cence greater than 90% or less than 10% in all but three 
instances (Additional file  2). One late treatment fail-
ure in the Zaire AL arm had a posterior probability of 
recrudescence of 29%, and two late treatment failures 
in the Zaire ASAQ arms had probabilities of 19 and 
39%. Four cases of recrudescence were identified in the 
Zaire AL arm, three in the Lunda Sul AL arm, and five 
in the Zaire ASAQ arm. No recrudescences were found 
among participants in the Benguela DP, Lunda Sul DP, 
or Benguela ASAQ arms.
After exclusion of reinfections, the corrected 28-day 
efficacy of AL was 96% (91–100%), in Zaire and 97% 
(93–100%) in Lunda Sul. The corrected 28-day efficacy 
of ASAQ was 100% (97–100%) in Benguela and 93% (88–
99%) in Zaire. The corrected 42-day efficacy of DP was 
100% (96–100%) in Benguela and 100% in Lunda Sul.
Safety
Among the 586 participants enrolled within inclusion 
criteria, 11 participants (2%) reported adverse medica-
tion effects: four with vomiting after DP (2% of partici-
pants in DP arms), three with nausea after ASAQ (2%), 
two with excessive sweating after ASAQ (1%), one with 
vomiting after ASAQ (1%), and one with excessive sweat-
ing after DP (1%). No participants reported adverse 
effects after AL administration, neither under direct 
observation nor at home. No participants left the study 
due to adverse medication effects.
Molecular markers of resistance
Almost all (75/76, 99%) of the day 0 and day of failure 
samples analysed from the 38 treatment failures were 
wild-type for pfk13 (Table  5). One sample from Zaire 
exhibited the A504V mutation, which has not been 
Table 1 Number of participants enrolled and finishing follow-up and characteristics at baseline
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
a 28-day follow-up
b 42-day follow-up
Benguela Zaire Lunda Sul
DPb ASAQa ALa ASAQa ALa DPb
Enrollment and follow-up
 Enrolled, n 100 105 100 98 105 100
 Lost to follow up, 
n (%)
5 (5) 2 (2) 3 (3) 5 (5) 5 (5) 7 (7)
 Excluded, n (%) 10 (10) 12 (11) 3 (3) 3 (3) 9 (9) 4 (4)
 Reached study 
endpoint, n (%)
85 (85) 91 (87) 94 (94) 90 (92) 91 (87) 89 (89)
Participant characteristics at baseline
 Median age, years 
(range)
7.1 (2–12) 6.3 (2–12) 3 (0.5–5) 2.7 (0.8–5) 3.3 (0.6–5) 3 (0.5–5)
 Median weight, kg 
(range)
20 (9–48) 19 (10–52) 12 (7–20) 12 (7–19) 12 (6–20) 12 (6–19)
 Percent female (%) 53 53 46 55 54 47
 Median day 0 
parasitaemia, 
parasites/µL 
(range)
25,940 (1218–
95,585)
31,399 (1242–
97,167)
47,607 (2175–
182,138)
31,215 (2848–
184,243)
22,340 (2162–
122,064)
19,812 (3316–
184,465)
 Median day 0 
haemoglobin, g/
dL (range)
10.5 (8.1–13.9) 10.7 (8.1–15.1) 10.1 (8.1–13.0) 9.7 (8.1–13.0) 9.5 (8.1–12.8) 9.3 (8.1–14.9)
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associated with artemisinin resistance. Nearly all day of 
failure samples in the AL arms carried the pfcrt wildtype 
K76 genotype (14/16, 88%), and all had the N86 pfmdr1 
genotype (16/16, 100%). All ASAQ day of failure sam-
ples (17/17, 100%) carried the pfcrt 76T single-nucleotide 
polymorphism. The only two samples with the pfmdr1 
86Y mutation were ASAQ day of failure samples from 
Benguela.
All 76 analysed samples had only one copy of both the 
pfmdr1 and pfpm2 genes. However, 75 of 76 samples con-
tained multiple P. falciparum strains.
Lumefantrine concentrations
Median day 7 lumefantrine concentrations in the Zaire 
AL arm were similar among participants experiencing 
adequate clinical and parasitological response, reinfec-
tion, and recrudescence, ranging from 0.19 to 0.23  μg/
mL (Additional files 3, 4). Two (50%) out of the four cases 
of recrudescence observed in the AL arm had sub-ther-
apeutic day 7 lumefantrine levels, but this did not differ 
significantly (p value 1.0) from rate of sub-therapeutic 
day 7 lumefantrine levels in participants with adequate 
clinical and parasitological response (35/87, 40%). Two 
children had undetectable lumefantrine levels, one of 
whom successfully responded to treatment and one of 
whom had a recrudescent infection. The distribution of 
day 7 lumefantrine concentrations was not statistically 
different between cases of adequate clinical and para-
sitological response and recrudescence (p value 0.94), 
between cases of adequate clinical and parasitological 
Table 2 Treatment outcomes for participants finishing follow-up
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
a 28-day follow-up
b 42-day follow-up
n (%)
Benguela Zaire Lunda Sul
DPb ASAQa ALa ASAQa ALa DPb
n = 85 n = 91 n = 94 n = 90 n = 91 n = 89
Treatment failure 5 (6) 1 (1) 7 (7) 16 (18) 9 (10) 0
 Early treatment failure 0 0 0 0 0 0
 Late treatment failure 5 (6) 1 (1) 7 (7) 16 (18) 9 (10) 0
 Recrudescence 0 0 4 (4) 5 (6) 3 (3) 0
  Day 21 0 0 1 (1) 5 (6) 3 (3) 0
  Day 28 0 0 3 (3) 0 0 0
  Day 35 0 – – – – 0
  Day 42 0 – – – – 0
 Reinfection 5 (6) 1 (1) 3 (3) 11 (12) 6 (7) 0
  Day 21 0 0 0 7 (8) 2 (2) 0
  Day 28 0 1 (1) 3 (3) 4 (4) 4 (4) 0
  Day 35 2 (2) – – – – 0
  Day 42 3 (4) – – – – 0
Adequate clinical and parasitologi-
cal response
80 (94) 90 (99) 87 (93) 74 (82) 82 (90) 89 (100)
Table 3 Proportion of slides negative for asexual malaria parasites on days 2 and 3 following treatment
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
Proportion slides negative (95% confidence intervals)
Benguela Zaire Lunda Sul
DP ASAQ AL ASAQ AL DP
Day 2 98 (92–100) 100 (95–100) 97 (91–99) 97 (91–99) 97 (91–99) 100 (95–100)
Day 3 100 (95–100) 100 (95–100) 100 (95–100) 100 (95–100) 100 (95–100) 100 (95–100)
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response and reinfection (p value 0.34), or between cases 
of adequate clinical and parasitological response and 
recrudescence/reinfection (0.80).
Discussion
AL, ASAQ, and DP remain efficacious for the treatment 
of uncomplicated P. falciparum malaria in the sites where 
they were tested. The WHO recommends changing 
national malaria treatment policy if efficacy drops below 
90% [2], and all corrected efficacies reported here exceed 
that threshold. All three medications were very well tol-
erated, with less than 2% of participants experiencing 
mild adverse effects and no participants experiencing 
serious adverse effects.
Uncorrected therapeutic efficacy was above 90% in all 
study arms except ASAQ in Zaire, which had an uncor-
rected efficacy of 82%. Low uncorrected efficacy has been 
noted in previous anti-malarial studies in Zaire [6, 7] and 
may be explained in part by relatively high malaria trans-
mission in this province as compared to the other sites.
There has been concern recently around possible lume-
fantrine resistance in Angola, particularly in Zaire. The 
results presented here do not support this concern, with 
corrected AL efficacy at 96% in Zaire and 97% in Lunda 
Sul. Greater efforts to administer all AL doses with a 
fatty meal could explain the higher lumefantrine efficacy 
observed in this round of monitoring. Nevertheless, a 
substantial proportion (40%) of cases of adequate clinical 
and parasitological response had day 7 lumefantrine con-
centrations below the recommended therapeutic thresh-
old of 0.2  μg/mL. There was no statistically significant 
difference in day 7 lumefantrine drug levels by treatment 
outcome in the AL Zaire arm, but this could be due to the 
small number of treatment failures observed in that arm.
DP demonstrated the highest efficacy of all anti-
malarials in this study, with no recrudescences identified 
throughout 42 days of follow-up among 174 participants 
taking this medication. This high efficacy, combined with 
the drug’s relatively long half-life, confirms DP as an 
appropriate ACT for Angola [32]. Although the utility of 
this medication is declining in Asia, DP efficacy remains 
high throughout Africa [33].
Multiple factors provide reassurance that P. falciparum 
is still highly susceptible to artemisinin derivatives in 
Angola. No early treatment failures were observed in this 
study. Parasite clearance was rapid in all study arms, with 
parasitaemia resolving in at least 97% of participants by 
day 2 of follow-up and all participants by day 3. Finally, 
no mutations in pfk13 associated with artemisinin resist-
ance were identified during molecular analysis of treat-
ment failures.
In contrast to the previous rounds of therapeutic effi-
cacy studies [6, 7], the minimum haemoglobin required 
for inclusion was increased to 8 g/dL from 5 g/dL, pos-
sibly explaining why no early treatment failures were 
observed in the current round. All but one of the early 
treatment failures observed in both the 2013 and 2015 
studies were due to severe anemia. A haemoglobin 
of less than 5  g/dL in the presence of parasitaemia is a 
sign of severe malaria and, if observed during follow up, 
would prompt concern for treatment failure. However, 
it is common for patients on anti-malarial treatment to 
Table 4 Efficacy of first-line anti-malarials in three therapeutic efficacy monitoring sites in Angola, 2017
Per-protocol efficacy defined as proportion adequate clinical and parasitological response, Kaplan–Meier estimate calculated from estimate of survival function
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
a 28-day follow up
b 42-day follow up
Efficacy (95% confidence intervals)
Benguela Zaire Lunda Sul
DPb ASAQa ALa ASAQa ALa DPb
Uncorrected
 Per-protocol day 28 100 (95–100) 99 (94–100) 92.8 (85–97) 82.2 (72–89) 90.1 (82–95) 100 (95–100)
 Per-protocol day 42 94.6 (87–98) – – – – 100 (95–100)
 Kaplan–Meier estimate day 28 100 (100–100) 98.9 (97–100) 92.7 (88–98) 82.1 (75–90) 90.1 (84–96) 100 (100–100)
 Kaplan–Meier estimate day 42 94.6 (90–99) – – – – 100 (100–100)
PCR-corrected
 Per-protocol day 28 100 (97–100) 100 (97–100) 95.5 (89–98) 93 (85–97) 96.4 (90–99) 100 (96–100)
 Per-protocol day 42 100 (96–100) – – – – 100 (96–100)
 Kaplan–Meier estimate day 28 100 100 (97–100) 95.5 (91–100) 93.3 (88–99) 96.5 (93–100) 100
 Kaplan–Meier estimate day 42 100 (96–100) – – – – 100
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experience an initial drop in haemoglobin before improv-
ing. Children enrolled with a haemoglobin near 5  g/dL 
who undergo this customary decrease may be inappro-
priately classified as early treatment failures, when in fact 
they were following the expected treatment course.
Analysis of markers of partner drug resistance in AL 
and ASAQ treatment failures yielded results consistent 
with previous understanding of these resistance markers. 
Mutations in pfcrt K76 and pfmdr1 N86 are known to be 
associated with AL resistance [17], and these were pre-
sent on day of failure in nearly all AL treatment failures. 
The pfcrt K76T genotype, which has been associated 
with decreased ASAQ susceptibility [17], was identi-
fied in all ASAQ treatment failures from this study. The 
only instances of a pfmdr1 86Y mutation, associated with 
amodiaquine resistance, were identified in ASAQ treat-
ment failures.
As AL and ASAQ exhibit opposite selective pressures 
on certain loci in the pfmdr1 and pfcrt genes, alternat-
ing the use of these drugs might preserve diversity in 
these genes and minimize the emergence of resistance. 
Analysis of day 0 samples from the 2015 therapeutic effi-
cacy study has shown that the majority of parasites cir-
culating in the three sentinel provinces in Angola carry 
the pfmdr1 N86 genotype [34]. A similar analysis of all 
day 0 samples from this current study could be useful in 
characterizing how the circulating parasite population is 
affected by the selective pressures on the pfmdr1 gene.
None of the day 0 or day of failure samples had an ele-
vated copy number of pfmdr1, consistent with the gen-
eral absence [35, 36] or low rates [37, 38] of pfmdr1 copy 
number variation in sub-Saharan Africa. As a recently 
proposed marker, there are few available data on pfpm2 
copy number variation in sub-Saharan Africa; absence 
of elevated copy number in this gene in the samples ana-
lysed here is consistent with relatively low rates of DP use 
in sub-Saharan Africa. However, all but one of the sam-
ples analysed for copy number variation contained mul-
tiple P. falciparum strains, so this analysis of could have 
missed an elevated copy number in parasites occurring at 
low-frequencies in mixed-strain infections.
Although the study was carried out in three provinces 
of Angola with varied geography and malaria endemicity, 
it is possible that these results may not be representative 
of either any one province or the entire country. Fur-
thermore, since assignment of treatment drug was not 
random, drug efficacies should not be compared across 
study arms.
Conclusions
All three evaluated artemisinin-based combinations 
continue to be efficacious against P. falciparum malaria 
in the three sentinel sites in Angola. Rapid parasite 
clearance is consistent with full susceptibility to arte-
misinin derivatives. Periodic monitoring of in vivo drug 
efficacy remains a critical routine activity for the Ango-
lan NMCP.
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